Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HL151 in Healthy Male Subjects
NCT02682745Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bepotastine in perennial allergic rhinitis (PAR) (6 arms), sponsored by Hanlim Pharm. Primary endpoints: Area under the plasma concentration versus time curve at 24 hours and Peak Plasma Concentration at 24 hours. Started Jan 2016; status: completed.
02
Drugs
bepotastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT02682745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682745.